 "Lupin steps up focus on biosimilars with an eye on $24 bn global market")
Lupin will increase increase investments in its biotech business as it looks to build a pipeline of seven biosimilars with a total market size of $24 billion. Biosimilars are copies of innovative biologic drugs and are made from living cells.
On Wednesday the drug maker announced the successful outcome of global phase III trial for biosimilar Etanercept which is indicated for treatment of rheumatoid arthritis.
Etanercept is a copy of Amgen's $11 billion drug Enbrel. Lupin is developing the drug in a joint venture partnership with Japanese drug maker Yoshindo.
“We are working on strategies to invest only as necessary and supplement
